Y-mabs therapeutics announces resignation of chief financial officer

New york, march 14, 2024 (globe newswire) -- y-mabs therapeutics, inc. (the “company” or “y-mabs”) (nasdaq: ymab), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced that chief financial officer, bo kruse, has notified the company of his resignation. y-mabs has commenced a search process for a successor. mr. kruse will remain in the chief financial officer role until his successor is identified and joins the company. he will then continue as a non-executive employee from the time his successor joins the company through july 31, 2024, after which it is expected that mr. kruse will be available to the company for a period of time to support a smooth transition of the chief financial officer role.
YMAB Ratings Summary
YMAB Quant Ranking